RiverVest Venture Partners® is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors.

With headquarters in St. Louis and offices in San Diego and Cleveland, RiverVest accesses forward-thinking research and clinical expertise at leading institutions across the country to found and fund biopharma and medical device companies.

Entrepreneurs turn to RiverVest for the scientific, operational, financial, and investment expertise they need to achieve long-term success. RiverVest is committed to doing business the right way to deliver the best outcomes for patients, entrepreneurs and investors.

Established in 2000, RiverVest has funded more than 60 innovative life science companies and has assets under management of approximately $750 million.  For more information, please visit http://www.rivervest.com.

ZS Pharma

CardiaLen

Lumena Pharmaceuticals

Securus Medical Group

Smart Wires

Spruce Biosciences

Standard Bariatrics

Good Therapeutics

Otonomy

Mirum Pharmaceuticals

Accumetrics

Xilio Therapeutics, Inc.

Allakos

Amplyx Pharmaceuticals

Reneo Pharmaceuticals

RiverVest Venture Partners

RiverVest portfolio company Good Therapeutics, Inc. (now Bonum Therapeutics) is developing a new class of regulated protein therapeutics designed to deliver potent biological activity only where needed. These drugs could be a huge win for patients fighting cancer and other diseases. Roche acquired Good’s PD1-regulated IL-2 program in 2022 for $250 million plus potential milestone payments. We discuss that acquisition and more in RiverVest’s latest case study. Read it at rivervest.com or see a sample below.
 
In this case study, we recognize John Mulligan, Ph.D., Diane Hollenbaugh, John McKearn, the entire team at Bonum Therapeutics, and Roche.
 
Investor Syndicate: Codon Capital, Digitalis Ventures, RiverVest Venture Partners, Roche Venture Fund, and 503 Partners (formerly 3x5 Partners)
 
 #IL2 #PD1 #conditionallyactivetherapeutics #immunooncology #immunotherapy #biotech Neela Patel

At RiverVest, we find and fund innovation to address significant unmet medical needs and improve the lives of patients. During #WorldMitochondrialDiseaseWeek, we recognize the advocacy groups who support research into mitochondrial medicine that will one day lead to treatments and cures for #mito.
 
Read our recent article on the role of patient advocacy groups in drug development here: https://lnkd.in/gm6Sag7A
 
Reneo Pharmaceuticals Niall O'Donnell Wendy Newman Philip Yeske Alison Maguire Ashley H. Danielle Spangler MitoAction Mito Foundation Cure Mito Foundation The PolG Foundation and so many more! 

#MitoAwareness #mitochondrialdisease 

Patient advocacy groups are crucial to the development of drug therapeutics that are most impactful for the patient. For example, patient-derived data often include quality-of-life priorities that researchers don’t anticipate.

In RiverVest's latest "Expert Insight," we explore the role of patient advocacy groups in therapeutic drug development for patients with rare diseases. Learn how one #biopharma company is tackling mitochondrial disease by listening to the experts: the patients and families who live with the disease every day. 

Featured are United Mitochondrial Disease Foundation, Europe's The Lily Foundation, and Reneo Pharmaceuticals.

Niall O'Donnell  Philip Yeske Alison Maguire Wendy Newman Danielle Spangler Gregory J. Flesher Alejandro (Alex) Dorenbaum, M.D. Ashley H.

#raredisease #mito #mitochondrialdisease #PMM #LCFAOD #myopathy

RiverVest portfolio company Xilio Therapeutics, Inc. announced a collaboration with Roche to evaluate XTX101 anti-CTLA4 in combination with Roche’s atezolizumab in patients with microsatellite stable colorectal cancer. 

iSelect Fund is a venture capital firm that focuses on early-stage investments in innovative companies within the healthcare sector.

iSelect Fund

Permanent Equity is a venture capital firm that invests in early-stage healthcare companies, particularly those involved in medical devices, biopharmaceuticals, and healthcare services.

Permanent Equity

BW Forsyth Partners is a venture capital firm specializing in investments in the healthcare sector, with a focus on medical devices, biopharmaceuticals, and healthcare services.

BW Forsyth Partners

RiverVest Venture Partners is a venture capital firm that specializes in early-stage investments in the healthcare sector. The firm focuses on identifying and nurturing innovative companies that address significant unmet needs in the medical field, particularly in the areas of medical devices, biopharmaceuticals, and healthcare services.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	May 11, 2024 1:00 AM	ff7371d7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 11, 2024 1:00 AM	5b396cca
translate crunchbase fundingrounds	general
peers	general
news basic	general
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:RIVERVEST

RiverVest Venture Partners